カリナン･セラピューティクス
Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.84 | $0 | -$46M |
| 2025 Q4 | -0.86 | $0 | -$38M |
| 2025 Q3 | -0.86 | $0 | -$37M |
| 2025 Q2 | -1.19 | $0 | -$58M |
| 2025 Q1 | -0.82 | $0 | -$43M |
| 2024 Q4 | -0.81 | $0 | -$37M |
| 2024 Q3 |
| -0.70 |
| $0 |
| -$34M |
| 2024 Q2 | -0.76 | $0 | -$36M |